Anzeige
Mehr »
Mittwoch, 03.09.2025 - Börsentäglich über 12.000 News
Geheime Uran-Aktie: Ist das der historische "New Deal"-Moment für amerikanischen Uransektor?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A14M04 | ISIN: FR0012432516 | Ticker-Symbol: 7PO
Frankfurt
03.09.25 | 08:20
0,299 Euro
-0,99 % -0,003
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
POXEL SA Chart 1 Jahr
5-Tage-Chart
POXEL SA 5-Tage-Chart
RealtimeGeldBriefZeit
0,3040,30810:29

Aktuelle News zur POXEL Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
11.08.XFRA 7PO: WIEDERAUFNAHME/RESUMPTION178 FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME...
► Artikel lesen
08.08.Poxel SA: Poxel Announces the Opening of Reorganization Proceedings333POXEL shares to resume trading on August 11, 2025 at market opening Regulatory News: POXEL SA (Euronext: POXEL FR0012432516), a clinical stage biopharmaceutical company developing innovative...
► Artikel lesen
01.08.Poxel SA: Following the Filing for the Opening of Reorganization Proceedings, Poxel Announces Changes to Its Corporate Governance435Regulatory News: POXEL SA (Euronext: POXEL FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology...
► Artikel lesen
30.07.XFRA 7PO: AUSSETZUNG/SUSPENSION282DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILPOXEL S.A. EO -...
► Artikel lesen
POXEL Aktie jetzt für 0€ handeln
29.07.Poxel SA: Poxel Provides Update on Negotiations with Creditors and Announces Filing of Reorganization Proceedings, Upcoming Change of Corporate Governance and Suspension of Trading493Since the rejection of key financial delegations during its Shareholders General Meeting of February 11, 2025, triggering a case of default of certain of its existing debts, Poxel's management...
► Artikel lesen
30.06.Poxel SA: Poxel Announces Postponement of its Annual General Meeting and Provides a Corporate Update362Regulatory News: POXEL SA (Euronext: POXEL FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology...
► Artikel lesen
19.06.Poxel SA: New Scientific Presentations by Key Opinion Leaders to Further Highlight the Therapeutic Potential of Imeglimin at ADA 2025, the Leading Diabetes Conference294Regulatory News: POXEL SA (Euronext: POXEL FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology...
► Artikel lesen
28.05.POXEL SA: New Clinical and Scientific Data on TWYMEEG to be Presented at the 68th Annual Meeting of the Japan Diabetes Society441Regulatory News: POXEL SA (Euronext: POXEL FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology...
► Artikel lesen
26.05.Poxel SA: Poxel Announces Positive Preclinical Data for PXL065 in Hypertrophic Cardiomyopathy To Be Presented at the ESC Congress 2025447PXL065 demonstrated significant benefits in a HCM mouse model preventing pathological myocardial remodeling, including hypertrophy and fibrosis in the heart Presentation of detailed results...
► Artikel lesen
13.05.Poxel Reports Consolidated Revenue for the First Quarter 2025 and Provides Corporate Update317TWYMEEG consolidated gross sales in Japan for Sumitomo Pharma Fiscal Year 20241 achieved JPY 7.6 billion (EUR 47,2 million)2, in line with Sumitomo Pharma's latest guidance3 Sumitomo Pharma...
► Artikel lesen
16.04.POXEL SA: Poxel Provides Financial Update for the First Quarter 2025 and Announces the Postponement of its 2024 Full-Year Results579Non-adoption of key financial delegations at the Combined General Meeting held on February 11, 2025 resulted in an adverse and uncertain situation regarding the continuation of the Company's...
► Artikel lesen
08.04.POXEL SA: Poxel Announces Regulatory Approval by Japanese Authorities to Expand TWYMEEG Package Insert to Include Type 2 Diabetes Patients with Renal Impairment645Approval by the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan enables TWYMEEG (Imeglimin) to be prescribed to type-2 diabetic patients with moderate to severe renal impairment. This...
► Artikel lesen
31.03.Poxel SA: Poxel Announces Grant of New Patent in Japan for the Use of Imeglimin in Type-2 Diabetic Patients with Renal Impairment452Newly granted patent covers Imeglimin's use in type-2 diabetic patients with renal impairment and has a patent term in Japan until 2039 This patent further supports Poxel's strategy to...
► Artikel lesen
20.03.Poxel SA: Poxel Announces Positive Results from a Preclinical Study for PXL065, a Proprietary Deuterium-Stabilized R-Stereoisomer of Pioglitazone, in Hypertrophic Cardiomyopathy529Hypertrophic cardiomyopathy (HCM) is the most common human genetic cardiac disorder and can lead to serious complications including heart failure and sudden cardiac death The preclinical...
► Artikel lesen
19.02.POXEL SA: Poxel Reports Revenue for the Full Year 2024 and Provides an Update on its Financial Position and Outlook885Following the non-adoption of key financial delegations at the Combined General Meeting held on February 11, 2025, the Company is facing an uncertain and adverse situation regarding the continuation...
► Artikel lesen
11.02.POXEL SA: Poxel Announces Results of its Combined General Meeting Held on February 11, 2025504Regulatory News: POXEL SA (Euronext: POXEL FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology...
► Artikel lesen
31.01.POXEL SA: Poxel's partner Sumitomo Pharma reports TWYMEEG gross sales in Japan for Q4 2024 and FY 2024 sales forecast766TWYMEEG sales continued to increase in Japan for the last quarter 2024 (October-December) by 17% over the prior quarter and by 154% over Q4 2023 TWYMEEG's FY 20241 revised forecast2 of...
► Artikel lesen
23.01.Poxel SA: Poxel Announces its Financial Calendar for 2025471Regulatory News: POXEL SA (Euronext: POXEL FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology...
► Artikel lesen
21.01.Poxel: Ordinary and Extraordinary General Meeting to Be Held on February 11, 2025468Poxel announces that a Combined General Meeting will be held on February 11, 2025, at 9:00 a.m. CET and the availability of the preparatory documents Poxel announces the addition of a new...
► Artikel lesen
20.01.Poxel Announces the Grant of Patent in China Protecting the Use of Imeglimin for Type-2 Diabetic Patients with Renal Impairment449Patent life covering Imeglimin in China extended to 2039 Ongoing partnership discussions to develop and market Imeglimin in China, the world's second largest type 2 diabetes market Regulatory...
► Artikel lesen
Weiter >>
33 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1